Business Wire

LFB-SA

18.4.2016 15:39:14 CEST | Business Wire | Press release

Share
2015, a Strategic Year for LFB

Key events in 2015 :

  • Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
  • Two new products registered in Europe
  • Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
  • Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
  • Turnover of €502.4 million, stable in comparison to 2014

Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In 2015, the key milestones have been successfully achieved. It has been a historic and productive year for the future of LFB."

An unprecedented increase in capital in order to finance the group's development
As part of the group's strategic development, LFB's shareholder (the French State) decided in October to underwrite an increase in LFB's share capital by €230 million. The share capital of the company now stands at €280 million. To meet the financing needs of LFB's development project, on 5 January 2016 LFB issued a senior bond of €124 million. These funds will enable the construction of a 'new generation' plant in Arras. This flagship project, representing an investment of approximately €300 million, will enable LFB to triple its global production capacity in 2020 with facilities aimed at manufacturing for the whole world.
LFB is also developing its sites in Alès (Gard) and Charlton (USA), establishing bio-production facilities for recombinant medicines in development.

Consolidated earnings in €M

  2015   2014   Variation 2015/2014

Turnover

 

502.4

 

501.9

 

0.1 %

Gross margin

 

177.6

 

195.5

 

-9.2 %

Research & development

 

(81.3)

 

(65.9)

   

Commercial costs

 

(51.0)

 

(48.6)

 

General costs

 

(50.3)

 

(48.7)

 

Other charges and
operational income

 

17.0

 

(7.1)

 

Operational earnings

 

12.0

 

25.2

 

as a % of turnover

 

2.4 %

 

5.0 %

 

Net earnings

 

0.3

  13  

€90.5 million* before research tax credit

2015 turnover - growth in international sales
At €502.4 million, turnover is relatively stable as compared to 2014. For the second successive year, the group's turnover exceeded €500 million, with the international side business continuing to grow. Despite a 3.2 % decline in turnover in France during 2015, international sales rose by €12.1 million (+8.7%), reaching €152 million. This figure represents 30% of consolidated turnover (28% in 2014).

Operational earnings decline in order to finance strategy
Research and development costs are increasing rapidly (€81.3 million), owing to the large number of phase III trials in progress. Various strategic projects reached significant milestones. In 2015, two new LFB products, a 10% immunoglobulin and a fibrinogen have been subject to a mutual recognition in procedure in Europe with the Paul Ehrlich Institute as the referral agency. Two other recombinant products are currently at the end of phase III. At the same time, LFB is planning to manufacture product batches for launch, which has had an impact on earnings. In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive operational earnings (€12.0 million) is down as compared to that of 2014 (-13.2 million) due to a decline in gross margins and increased development costs. Despite this unprecedented effort, net earnings remain positive at €0.3 million.

About LFB Group
LFB is a bio-pharmaceutical company that develops, manufactures, and markets medicinal products from living systems for the treatment of serious and often rare diseases in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care. Currently ranked 6th worldwide in the field of plasma-derived medicinal products, LFB Group is also among the leading European companies in the development and production of proteins and innovative treatments derived from bio-technologies. It employs 2,111 staff worldwide.
http://www.groupe-lfb.fr

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact:

LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication Director
charrieres@lfb.fr
or
David Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Introduces BlueVerse™ OneToken with Harnessing Capabilities to Optimize Token Spend24.9.2026 10:30:00 CEST | Press release

Helps organizations run and scale AI with greater control, transparency and accountability LTM, the Business Creativity partner to the world’s largest enterprises, today announced BlueVerse™ OneToken, a workload routing and governance layer with Harnessing Capabilities that automatically channels enterprise AI requests to the right model at the right cost. As enterprises scale agentic workflows, requests are often routed to expensive frontier models even when lower-cost options can deliver the required outcome. BlueVerse OneToken manages model selection across workloads including code, voice, service, research and agents, matching each task with the most appropriate model, based on the client’s quality, security and performance requirements. Clients can deploy BlueVerse OneToken over their existing AI environment, giving them a single subscription for AI consumption enabling them to consume AI through their existing cloud providers using OneToken plug-ins, available across AWS, Google

MVC Group Acquires Tailfin, Entering the Premium Bikepacking Sector24.9.2026 10:30:00 CEST | Press release

The acquisition expands MVC's portfolio with best-in-class solutions in a category highly complementary to Castelli and Sportful's technical cycling apparelTailfin will accelerate its international expansion through synergies with MVC Group's global platform MVC Group, a group specialising in technical apparel for cycling and outdoor sports, announces the acquisition of Tailfin, the global leader in the premium technical bikepacking segment. Founded in Bristol in 2017 by Nick Broadbent – CEO, mechanical engineer and product designer – Tailfin has rapidly established itself as a leading international name in premium bikepacking bags, racks and accessories, combining design and performance with a strong focus on innovation. The company has developed proprietarytechnologies protected by more than 20 granted and pending patents, building a leading position based on engineering excellence, materials research and rigorous product development and validation processes. Over the past five years

CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors24.9.2026 09:49:00 CEST | Press release

CAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors. “We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors,” said Edouard Fonck, Chief Executive Officer of CAIRDAC, “Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project.” Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience. He was the co-founder and CEO of Axonics, Inc. (Nasdaq: AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics was recognized as the fastest-growing technology company in North America generating over $1.2 billion in revenue in the four years

Glass Lewis and Clarity AI Join Forces to Integrate Sustainability, Governance and Stewardship24.9.2026 09:30:00 CEST | Press release

Integrated platform will connect investment and stewardship decisions through trusted data, AI analytics, and technology Glass Lewis and Clarity AI today announced their combination, merging Clarity AI’s advanced technology, deep sustainability data, AI analytics, and strong European market presence with Glass Lewis’ global expertise across corporate governance, proxy voting and investment stewardship. The strategic combination significantly expands the firms’ ability to serve European institutional investors and companies through enhanced local market expertise, broader sustainability capabilities and faster product development that addresses Europe’s evolving regulatory and stewardship requirements. The integrated platform fills a solutions gap as institutional investors increasingly seek to bring together investment analysis, sustainability, governance, engagement and voting rather than manage them through separate systems, datasets and workflows. At the same time, companies are con

Wolters Kluwer integrates Libra AI workflows into monKEY for Belgian tax professionals24.9.2026 09:00:00 CEST | Press release

The add-in of Libra by Wolters Kluwer brings AI capabilities directly into monKEY’s trusted tax research environment and marks an important milestone in further expanding Libra’s presence across different customer segments Wolters Kluwer Legal & Regulatory today announced the integration of Libra AI workflows in monKEY, its research platform for tax professionals in Belgium. The add-in of Libra by Wolters Kluwer enables customers to directly access Libra’s AI capabilities from the trusted research environment in monKEY, combining generative AI with tax research based on long-trusted expert content. “By integrating Libra into monKEY, we are taking another important step towards connected, AI-powered workflows for our customers,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “We are bringing together the power of AI and the trusted, up-to-date tax content professionals rely on every day. This helps them reach relevant insights faster w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye